skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Informa pharma logo

Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC

This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Pharma Intelligence Logo
Search Icon Pharma Report StoreRecommendationsProduct loginProductLogin
Global Search Configuration

Established Jun 2015, Q BioMed, the NYC-based biomedical acceleration development company, is looking to add additional assets to its portfolio. Company founder and CEO Denis Corin describes the progress Q BioMed has made with its first two assets and outlines his ambition to expand further in the coming two to three years.

 

Q BioMed Plans 

 

Q BioMed founder and CEO Denis Corin met Scrip's Mike Ward and provided an update on the company's progress since its founding in June 2015. A biomedical acceleration development company based in New York, the company has now signed two deals, one for an early-stage glaucoma asset and the other for an FDA-approved, first-in-class non-narcotic generic to treat metastatic bone cancer pain that is ready to take to market. Q BioMed is therapeutic area agnostic and is looking to establish a portfolio of hitherto neglected assets from early R&D to commercial-ready, which it will bring to a value inflection point.

 

He acknowledges that capital is a constraint but points out that the company has derisked itself by acquiring a revenue-ready asset and is now looking to acquire four or five more assets over the next two to three years. These could be from private sources or public companies.

 

 

 

This interview was recorded at EBD Group's Biotech Showcase in San Francisco in January 2017. (Also see " Video Interview: Q BioMed Accelerates Advances In Vascular Therapeutics " - Scrip, 15 Mar, 2016.)

Read also

;

Next steps

Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.

Start a free trial

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.
General enquiry

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now:

Shop now